Nicotinic Acid vs Niacinamide: Flushing, Hepatotoxicity, and Why the Form Matters

"Niacin" on a supplement label can mean two very different molecules. Nicotinic acid (also called niacin) and niacinamide (nicotinamide) both convert to NAD in the body and both prevent the deficiency disease pellagra. They diverge sharply on flushing, lipid effects, hepatotoxicity, and the conditions where they have been clinically useful. Confusing the two is a common source of unwanted side effects and of inappropriate use.

Where the molecules act differently

Nicotinic acid binds the GPR109A receptor on adipocytes, suppressing fatty acid release and lowering very-low-density lipoprotein production. It also binds GPR109A on Langerhans cells in the skin, triggering prostaglandin D2 release — the well-known "niacin flush" of warmth and erythema. Niacinamide does not bind GPR109A meaningfully and produces neither lipid effects nor flushing [1].

Lipid use of nicotinic acid is mostly historical

Nicotinic acid at 1–3 g/day was the first agent ever shown to lower cardiovascular events in the Coronary Drug Project (1975). It raises HDL roughly 15–25%, lowers triglycerides 20–50%, and modestly reduces LDL [2]. The AIM-HIGH and HPS2-THRIVE trials in the 2010s, however, showed no incremental benefit of niacin added to statin therapy and an increased risk of bleeding, infection, and serious adverse events [3]. Most cardiology guidelines now reserve niacin for very specific lipid disorders.

Hepatotoxicity — and the immediate vs sustained-release distinction

Nicotinic acid hepatotoxicity is dose- and formulation-dependent. Sustained-release formulations marketed as "no-flush" carry a substantially higher risk of severe hepatic injury, including fulminant hepatic failure, than immediate-release at equivalent doses [4]. Inositol hexanicotinate ("flush-free niacin") releases negligible nicotinic acid in vivo and probably does not deliver lipid benefits — but also carries less hepatotoxicity risk because it is not bioactive in the same way [5].

Niacinamide — different uses, different problems

Niacinamide does not lower cholesterol but has been studied for non-melanoma skin cancer prevention (the Australian ONTRAC trial showed reduced new actinic keratoses at 500 mg twice daily over 12 months) [6] and for certain inflammatory dermatoses. It has been studied at much higher doses (3 g/day) for osteoarthritis pain with modest effect. At doses above 3 g/day, hepatotoxicity, glucose intolerance, and thrombocytopenia have been reported [7].

Special situations

Patients on statins should not use high-dose nicotinic acid without specialist input given the rhabdomyolysis interaction signal. People with diabetes can experience worsened glycaemic control on either form at gram-level doses. Anyone with chronic liver disease should avoid sustained-release nicotinic acid entirely. Pregnancy doses should not exceed RDA levels (18 mg/day) absent specific medical indication [8].

Practical takeaway

For ordinary nutritional purposes, the form barely matters and both prevent pellagra at well under 50 mg/day. For lipid management, talk to a clinician — nicotinic acid's role has narrowed since AIM-HIGH and HPS2-THRIVE. For dermatology indications such as actinic keratosis prevention, niacinamide at 500 mg twice daily has the better trial evidence. Avoid the "high-dose flush-free" sustained-release products entirely — they pair the most serious risk (hepatotoxicity) with the least clear benefit.

How to recognise which form a label is actually selling

Confusion is common. "Niacin" on a vitamin label can mean nicotinic acid, niacinamide, or inositol hexanicotinate. Look for the molecular form spelled out below the headline number. "Flush-free niacin" almost always means inositol hexanicotinate. "No-flush extended-release niacin" usually means slow-release nicotinic acid — this is the formulation associated with the worst hepatotoxicity. "Nicotinamide" or "niacinamide" are the same molecule. Knowing what you have is the first step in deciding whether it suits the use case.

Special note on niacinamide riboside and NMN

Niacinamide is sometimes confused with the newer NAD-precursor supplements nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). They are related but not identical. NR and NMN raise tissue NAD modestly in human trials but have not shown the cardiovascular or skin-cancer prevention effects of nicotinic acid or niacinamide respectively. The older B-vitamin chemistry has stronger outcome data; the newer "NAD precursors" have stronger biomarker data with less outcome confirmation.